KÜLEON

Küleon is a drug discovery and development company leveraging proprietary, AI-based technology to identify novel serotonergic drugs for the targeted treatment of various neuropsychiatric diseases and disorders... We are passionate about our mission to bring better treatments to serious neuropsychiatric diseases and disorders, and welcome you to reach out. From investing in Küleon to academic collaborations and open job applications, we are happy to explore potential ways to collaborate with you... We have created a vast library of patentable and highly active new chemical entities (NCEs) that are designed to target serotonin receptors in a specific manner to enable the treatment of multiple neurological diseases and disorders.

Primary location: Seattle United States